Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss-Reference-Cited by-同舟云学术

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

Published:2018-07-23 Issue:3 Volume:25 Page:928-936
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

de Bono Johann S.,De Giorgi Ugo^ORCID,Rodrigues Daniel Nava,Massard Christophe,Bracarda Sergio,Font Albert,Arranz Arija Jose Angel^ORCID,Shih Kent C.,Radavoi George Daniel,Xu Na,Chan Wai Y.,Ma Han,Gendreau Steven,Riisnaes Ruth,Patel Premal H.,Maslyar Daniel J.,Jinga Viorel

Funder

Genentech (Genentech, Inc.)

F. Hoffman-La Roche (Hoffman-La Roche)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 247 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

2. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer;European Urology;2024-08

3. Androgen receptor post-translational modifications and their implications for pathology;Biochemical Society Transactions;2024-07-03

4. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group;Annals of Oncology;2024-07

5. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution;Cancer Cell;2024-07